STAAR appoints Warren Foust President and Chief Executive Officer
Warren Foust, previously COO and interim co-CEO, now joins the board; Deborah Andrews, interim co-CEO, becomes EVP while remaining CFO.
See the latest news and media coverage for STAAR. We track all announcements, press releases, and industry mentions in real time, all in one place.
Implantable lens designer and manufacturer
staar.comLast updated
In short: STAAR Surgical named Warren Foust as CEO and remained independent following the collapse of a $1.5 billion acquisition bid by Alcon.
Warren Foust, previously COO and interim co-CEO, now joins the board; Deborah Andrews, interim co-CEO, becomes EVP while remaining CFO.
Net sales expected to exceed $90 million, up from $44.3 million in Q2 2025.
Net sales reached $93.5 million, net income was $5.2 million, and Adjusted EBITDA totaled $24.4 million.
The company expects net sales in excess of $90 million for Q1, driven by China and Americas, and anticipates improved adjusted EBITDA.
Medical lens company STAAR Surgical (NASDAQ:STAA) will be reporting earnings this Wednesday after market hours. Here’s what ...
The implantable eye lens company began searching for a new CEO shortly after its sale to Alcon collapsed in January.
Alcon Inc. agreed to buy Staar Surgical Co. for about $1.5 billion, giving the Swiss eye-care firm access to a new vision-correction treatment.
STAAR Surgical Company STAA stock is trading lower on Friday after reporting preliminary net sales for the second quarter of over $90 million, compared to...
Track STAAR and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.